Silo Pharma secures global license for Alzheimer's drug, SPC-14, leveraging FDA's 505(b)(2) pathway.
Silo Pharma Inc (NASDAQ:SILO) shares surge on Tuesday due to an exclusive global license agreement for further developing, manufacturing, and commercializing its Alzheimer's drug, SPC-14. Silo plans to utilize the FDA's streamlined 505(b)(2) pathway, shortening clinical timelines and reducing drug development costs. The global Alzheimer's therapeutics market is projected to reach $30.8 billion by 2033.
July 16, 2024
3 Articles